Clinical Trials – the first step in the access conundrum

We are delighted to celebrate the launch of the National Clinical Trials Oversight Group (NCTOG) Report by Health Minister Jennifer Carroll MacNeill TD – a major step forward for Ireland’s clinical research landscape.
For the 300,000+ people living with rare diseases in Ireland, this announcement is especially meaningful – access to innovation can be life-changing. With more inclusive trials, easier access, and robust support infrastructure, people living with rare diseases will be better placed than ever to be active partners in research — rather than waiting on the sidelines.
Huge credit to NCTOG chair Donal Brennan and all members of the Oversight Group, including our CEO, Vicky McGrath, for their leadership and commitment. This is the kind of systemic change that can transform outcomes — and position Ireland as a leader in world-class clinical research.
We are absolutely 💯 serious about innovation, collaboration, and above all, putting patients first.
Key points worthy of note:

• More access to trials: The recommendations aim to significantly increase the number of clinical trials available in Ireland, bringing cutting-edge therapies closer to home for people with rare conditions.
• Faster, simpler trial start-up: Standardised contracts, costing frameworks and clearer data protection guidance will remove long-standing administrative hurdles.
• Stronger governance: A new Clinical Trials Advisory Council coming Q1 2026 will ensure patient voices — including those living with rare diseases — shape future development.
• Long-term coordination: The plan to establish a National Clinical Trials Body by 2027 will give Ireland the infrastructure needed to grow sustainably and compete globally.
• Greater transparency: A performance dashboard will support trust, accountability and better decision-making right across the system.
• Workforce development: Establish and execute a strategy to build and expand our clinical trials workforce, making Ireland a destination of choice for the best researchers, clinicians and trials professionals.